🔗 #StemCellEvidence link to:
Tisagenlecleucel for post-transplant relapse in young acute lymphoblastic leukemia patients: European real-world determinants of outcome
by Moser et al.
www.stemcellevidence.com/alerts/artic...
#MedSky
Tisagenlecleucel for post-transplant relapse in young acute lymphoblastic leukemia patients: European real-world determinants of outcome
by Moser et al.
www.stemcellevidence.com/alerts/artic...
#MedSky
Tisagenlecleucel for post-transplant relapse in young acute lymphoblastic leukemia patients: European real-world determinants of outcome
This multicenter real-world study identifies critical determinants of outcome for tisagenlecleucel (tisa-cel) in treating post-HSCT relapse in 220 children/young adults with B-ALL from 31 European cen...
www.stemcellevidence.com
November 3, 2026 at 4:51 PM
🔗 #StemCellEvidence link to:
Tisagenlecleucel for post-transplant relapse in young acute lymphoblastic leukemia patients: European real-world determinants of outcome
by Moser et al.
www.stemcellevidence.com/alerts/artic...
#MedSky
Tisagenlecleucel for post-transplant relapse in young acute lymphoblastic leukemia patients: European real-world determinants of outcome
by Moser et al.
www.stemcellevidence.com/alerts/artic...
#MedSky
🆕 From the #StemCellEvidence alert:
📑 Tisagenlecleucel for post-transplant relapse in young acute lymphoblastic leukemia patients: European real-world determinants of outcome
by Moser et al.
🔗 Link in the comments
#MedSky
📑 Tisagenlecleucel for post-transplant relapse in young acute lymphoblastic leukemia patients: European real-world determinants of outcome
by Moser et al.
🔗 Link in the comments
#MedSky
November 3, 2026 at 4:50 PM
🆕 From the #StemCellEvidence alert:
📑 Tisagenlecleucel for post-transplant relapse in young acute lymphoblastic leukemia patients: European real-world determinants of outcome
by Moser et al.
🔗 Link in the comments
#MedSky
📑 Tisagenlecleucel for post-transplant relapse in young acute lymphoblastic leukemia patients: European real-world determinants of outcome
by Moser et al.
🔗 Link in the comments
#MedSky
🔗 #StemCellEvidence link to:
Pregnancy outcomes in women conceiving after hematopoietic stem cell transplantation versus conventional chemotherapy for childhood or adolescent acute leukemia
by Guillerault et al.
www.stemcellevidence.com/alerts/artic...
#MedSky
Pregnancy outcomes in women conceiving after hematopoietic stem cell transplantation versus conventional chemotherapy for childhood or adolescent acute leukemia
by Guillerault et al.
www.stemcellevidence.com/alerts/artic...
#MedSky
Pregnancy outcomes in women conceiving after hematopoietic stem cell transplantation versus conventional chemotherapy for childhood or adolescent acute leukemia
Myeloablative conditioning before hematopoietic stem cell transplantation (HSCT) during childhood or adolescence reduces adult uterine volume, but its impact on future pregnancies remains uncertain. T...
www.stemcellevidence.com
November 3, 2026 at 2:07 PM
🔗 #StemCellEvidence link to:
Pregnancy outcomes in women conceiving after hematopoietic stem cell transplantation versus conventional chemotherapy for childhood or adolescent acute leukemia
by Guillerault et al.
www.stemcellevidence.com/alerts/artic...
#MedSky
Pregnancy outcomes in women conceiving after hematopoietic stem cell transplantation versus conventional chemotherapy for childhood or adolescent acute leukemia
by Guillerault et al.
www.stemcellevidence.com/alerts/artic...
#MedSky
➡️ New from the #StemCellEvidence alert:
📑 Pregnancy outcomes in women conceiving after hematopoietic stem cell transplantation versus conventional chemotherapy for childhood or adolescent acute leukemia
by Guillerault et al.
🔗Link in the comments
#MedSky
📑 Pregnancy outcomes in women conceiving after hematopoietic stem cell transplantation versus conventional chemotherapy for childhood or adolescent acute leukemia
by Guillerault et al.
🔗Link in the comments
#MedSky
November 3, 2026 at 2:06 PM
➡️ New from the #StemCellEvidence alert:
📑 Pregnancy outcomes in women conceiving after hematopoietic stem cell transplantation versus conventional chemotherapy for childhood or adolescent acute leukemia
by Guillerault et al.
🔗Link in the comments
#MedSky
📑 Pregnancy outcomes in women conceiving after hematopoietic stem cell transplantation versus conventional chemotherapy for childhood or adolescent acute leukemia
by Guillerault et al.
🔗Link in the comments
#MedSky
➡️ New from the #StemCellEvidence alert:
📑 Same-day rescue plerixafor during leukapheresis is safe and effective in allogeneic donors suboptimally responding to granulocyte colony-stimulating factor mobilization
by Hsu et al.
🔗 Link in the comments
#MedSky
📑 Same-day rescue plerixafor during leukapheresis is safe and effective in allogeneic donors suboptimally responding to granulocyte colony-stimulating factor mobilization
by Hsu et al.
🔗 Link in the comments
#MedSky
November 2, 2026 at 11:19 AM
➡️ New from the #StemCellEvidence alert:
📑 Same-day rescue plerixafor during leukapheresis is safe and effective in allogeneic donors suboptimally responding to granulocyte colony-stimulating factor mobilization
by Hsu et al.
🔗 Link in the comments
#MedSky
📑 Same-day rescue plerixafor during leukapheresis is safe and effective in allogeneic donors suboptimally responding to granulocyte colony-stimulating factor mobilization
by Hsu et al.
🔗 Link in the comments
#MedSky
🔗 #StemCellEvidence link to:
Same-day rescue plerixafor during leukapheresis is safe and effective in allogeneic donors suboptimally responding to granulocyte colony-stimulating factor mobilization
by Hsu et al.
www.stemcellevidence.com/alerts/artic...
#MedSky
Same-day rescue plerixafor during leukapheresis is safe and effective in allogeneic donors suboptimally responding to granulocyte colony-stimulating factor mobilization
by Hsu et al.
www.stemcellevidence.com/alerts/artic...
#MedSky
Same-day rescue plerixafor during leukapheresis is safe and effective in allogeneic donors suboptimally responding to granulocyte colony-stimulating factor mobilization
BACKGROUND: Plerixafor (P) is a rescue mobilization agent given to improve circulating CD34+ for peripheral blood stem cell (PBSC) collection in donors with inadequate response to granulocyte colony-s...
www.stemcellevidence.com
November 2, 2026 at 11:20 AM
🔗 #StemCellEvidence link to:
Same-day rescue plerixafor during leukapheresis is safe and effective in allogeneic donors suboptimally responding to granulocyte colony-stimulating factor mobilization
by Hsu et al.
www.stemcellevidence.com/alerts/artic...
#MedSky
Same-day rescue plerixafor during leukapheresis is safe and effective in allogeneic donors suboptimally responding to granulocyte colony-stimulating factor mobilization
by Hsu et al.
www.stemcellevidence.com/alerts/artic...
#MedSky
➡️ From the #StemCellEvidence alert:
📑 Effect of Stem Cell Cryopreservation on Day 60 Donor Chimerism in Unrelated Donor Allogeneic Stem Cell Transplantation Using Reduced-Intensity Conditioning and ATG-Based GVHD Prophylaxis
by Abduallah et al.
🔗 Link in the comments
#MedSky
📑 Effect of Stem Cell Cryopreservation on Day 60 Donor Chimerism in Unrelated Donor Allogeneic Stem Cell Transplantation Using Reduced-Intensity Conditioning and ATG-Based GVHD Prophylaxis
by Abduallah et al.
🔗 Link in the comments
#MedSky
November 2, 2026 at 12:50 PM
➡️ From the #StemCellEvidence alert:
📑 Effect of Stem Cell Cryopreservation on Day 60 Donor Chimerism in Unrelated Donor Allogeneic Stem Cell Transplantation Using Reduced-Intensity Conditioning and ATG-Based GVHD Prophylaxis
by Abduallah et al.
🔗 Link in the comments
#MedSky
📑 Effect of Stem Cell Cryopreservation on Day 60 Donor Chimerism in Unrelated Donor Allogeneic Stem Cell Transplantation Using Reduced-Intensity Conditioning and ATG-Based GVHD Prophylaxis
by Abduallah et al.
🔗 Link in the comments
#MedSky
🔗 #StemCellEvidence link to:
Effect of Stem Cell Cryopreservation on Day 60 Donor Chimerism in Unrelated Donor Allogeneic Stem Cell Transplantation Using Reduced-Intensity Conditioning and ATG-Based GVHD Prophylaxis
by Abduallah et al.
www.stemcellevidence.com/alerts/artic...
#MedSky
Effect of Stem Cell Cryopreservation on Day 60 Donor Chimerism in Unrelated Donor Allogeneic Stem Cell Transplantation Using Reduced-Intensity Conditioning and ATG-Based GVHD Prophylaxis
by Abduallah et al.
www.stemcellevidence.com/alerts/artic...
#MedSky
Effect of Stem Cell Cryopreservation on Day 60 Donor Chimerism in Unrelated Donor Allogeneic Stem Cell Transplantation Using Reduced-Intensity Conditioning and ATG-Based GVHD Prophylaxis
Cryopreservation of hematopoietic stem cell grafts has become more widely adopted. The impact of cryopreservation on clinical outcomes remains ambiguous, with existing studies limited by retrospective...
www.stemcellevidence.com
November 2, 2026 at 12:51 PM
🔗 #StemCellEvidence link to:
Effect of Stem Cell Cryopreservation on Day 60 Donor Chimerism in Unrelated Donor Allogeneic Stem Cell Transplantation Using Reduced-Intensity Conditioning and ATG-Based GVHD Prophylaxis
by Abduallah et al.
www.stemcellevidence.com/alerts/artic...
#MedSky
Effect of Stem Cell Cryopreservation on Day 60 Donor Chimerism in Unrelated Donor Allogeneic Stem Cell Transplantation Using Reduced-Intensity Conditioning and ATG-Based GVHD Prophylaxis
by Abduallah et al.
www.stemcellevidence.com/alerts/artic...
#MedSky
#StemCellEvidence link to:
Incidence, Patterns, and Outcomes of Fungal Infections in Patients With Graft Versus Host Disease Requiring Systemic Steroids Following Allogeneic Hematopoietic Cell Transplantation (...)
by Amin et al.
www.stemcellevidence.com/alerts/artic...
#MedSky
Incidence, Patterns, and Outcomes of Fungal Infections in Patients With Graft Versus Host Disease Requiring Systemic Steroids Following Allogeneic Hematopoietic Cell Transplantation (...)
by Amin et al.
www.stemcellevidence.com/alerts/artic...
#MedSky
Incidence, Patterns, and Outcomes of Fungal Infections in Patients With Graft Versus Host Disease Requiring Systemic Steroids Following Allogeneic Hematopoietic Cell Transplantation: A Systematic Revi...
BACKGROUND: Graft-versus-host disease (GVHD) is a significant complication following allogeneic hematopoietic cell transplantation (HCT). Systemic corticosteroids, the standard treatment for GVHD, inc...
www.stemcellevidence.com
October 29, 2026 at 7:15 AM
#StemCellEvidence link to:
Incidence, Patterns, and Outcomes of Fungal Infections in Patients With Graft Versus Host Disease Requiring Systemic Steroids Following Allogeneic Hematopoietic Cell Transplantation (...)
by Amin et al.
www.stemcellevidence.com/alerts/artic...
#MedSky
Incidence, Patterns, and Outcomes of Fungal Infections in Patients With Graft Versus Host Disease Requiring Systemic Steroids Following Allogeneic Hematopoietic Cell Transplantation (...)
by Amin et al.
www.stemcellevidence.com/alerts/artic...
#MedSky
From the #StemCellEvidence alert:
Incidence, Patterns, and Outcomes of Fungal Infections in Patients With Graft Versus Host Disease Requiring Systemic Steroids Following Allogeneic Hematopoietic Cell Transplantation: A Systematic Review and Meta Analysis
by Amin et al.
Link in the comments
#MedSky
Incidence, Patterns, and Outcomes of Fungal Infections in Patients With Graft Versus Host Disease Requiring Systemic Steroids Following Allogeneic Hematopoietic Cell Transplantation: A Systematic Review and Meta Analysis
by Amin et al.
Link in the comments
#MedSky
October 29, 2026 at 7:13 AM
From the #StemCellEvidence alert:
Incidence, Patterns, and Outcomes of Fungal Infections in Patients With Graft Versus Host Disease Requiring Systemic Steroids Following Allogeneic Hematopoietic Cell Transplantation: A Systematic Review and Meta Analysis
by Amin et al.
Link in the comments
#MedSky
Incidence, Patterns, and Outcomes of Fungal Infections in Patients With Graft Versus Host Disease Requiring Systemic Steroids Following Allogeneic Hematopoietic Cell Transplantation: A Systematic Review and Meta Analysis
by Amin et al.
Link in the comments
#MedSky
#StemCellEvidence link to:
GVHD prophylaxis with PTCy, ATG, PTCy+ATG, or no in vivo T-cell depletion in RIC matched-donor PBSC transplantation for AML and MDS
by Coman et al.
www.stemcellevidence.com/alerts/artic...
GVHD prophylaxis with PTCy, ATG, PTCy+ATG, or no in vivo T-cell depletion in RIC matched-donor PBSC transplantation for AML and MDS
by Coman et al.
www.stemcellevidence.com/alerts/artic...
GVHD prophylaxis with PTCy, ATG, PTCy+ATG, or no in vivo T-cell depletion in RIC matched-donor PBSC transplantation for AML and MDS
Post-transplant cyclophosphamide (PTCy) has transformed graft-versus-host disease (GVHD) prophylaxis but its role in matched-donor reduced-intensity allogeneic hematopoietic cell transplantation (allo...
www.stemcellevidence.com
October 29, 2026 at 7:24 AM
#StemCellEvidence link to:
GVHD prophylaxis with PTCy, ATG, PTCy+ATG, or no in vivo T-cell depletion in RIC matched-donor PBSC transplantation for AML and MDS
by Coman et al.
www.stemcellevidence.com/alerts/artic...
GVHD prophylaxis with PTCy, ATG, PTCy+ATG, or no in vivo T-cell depletion in RIC matched-donor PBSC transplantation for AML and MDS
by Coman et al.
www.stemcellevidence.com/alerts/artic...
➡️ New from the #StemCellEvidence alert:
📑GVHD prophylaxis with PTCy, ATG, PTCy+ATG, or no in vivo T-cell depletion in RIC matched-donor PBSC transplantation for AML and MDS
by Coman et al.
🔗Link in the comments
#MedSky
📑GVHD prophylaxis with PTCy, ATG, PTCy+ATG, or no in vivo T-cell depletion in RIC matched-donor PBSC transplantation for AML and MDS
by Coman et al.
🔗Link in the comments
#MedSky
October 29, 2026 at 7:24 AM
➡️ New from the #StemCellEvidence alert:
📑GVHD prophylaxis with PTCy, ATG, PTCy+ATG, or no in vivo T-cell depletion in RIC matched-donor PBSC transplantation for AML and MDS
by Coman et al.
🔗Link in the comments
#MedSky
📑GVHD prophylaxis with PTCy, ATG, PTCy+ATG, or no in vivo T-cell depletion in RIC matched-donor PBSC transplantation for AML and MDS
by Coman et al.
🔗Link in the comments
#MedSky
➡️ New from the #StemCellEvidence alert:
📑 Reduced-dose versus standard-dose total body irradiation before allogeneic haematopoietic stem cell transplantation in adults with acute lymphoblastic leukaemia
by Gruber et al.
🔗 Link in the comments
#MedSky
📑 Reduced-dose versus standard-dose total body irradiation before allogeneic haematopoietic stem cell transplantation in adults with acute lymphoblastic leukaemia
by Gruber et al.
🔗 Link in the comments
#MedSky
October 28, 2026 at 2:35 PM
➡️ New from the #StemCellEvidence alert:
📑 Reduced-dose versus standard-dose total body irradiation before allogeneic haematopoietic stem cell transplantation in adults with acute lymphoblastic leukaemia
by Gruber et al.
🔗 Link in the comments
#MedSky
📑 Reduced-dose versus standard-dose total body irradiation before allogeneic haematopoietic stem cell transplantation in adults with acute lymphoblastic leukaemia
by Gruber et al.
🔗 Link in the comments
#MedSky
🆕 From the #StemCellEvidence alert:
📑 Efficacy of post-transplant brentuximab vedotin maintenance by pre-transplant disease status in relapsed/refractory classic Hodgkin lymphoma
by Desai et al.
🔗Link in the comments
#MedSky
📑 Efficacy of post-transplant brentuximab vedotin maintenance by pre-transplant disease status in relapsed/refractory classic Hodgkin lymphoma
by Desai et al.
🔗Link in the comments
#MedSky
October 27, 2026 at 2:26 PM
🆕 From the #StemCellEvidence alert:
📑 Efficacy of post-transplant brentuximab vedotin maintenance by pre-transplant disease status in relapsed/refractory classic Hodgkin lymphoma
by Desai et al.
🔗Link in the comments
#MedSky
📑 Efficacy of post-transplant brentuximab vedotin maintenance by pre-transplant disease status in relapsed/refractory classic Hodgkin lymphoma
by Desai et al.
🔗Link in the comments
#MedSky
🔗 #StemCellEvidence link to:
Reduced-dose versus standard-dose total body irradiation before allogeneic haematopoietic stem cell transplantation in adults with acute lymphoblastic leukaemia
by Gruber et al.
www.stemcellevidence.com/alerts/artic...
Reduced-dose versus standard-dose total body irradiation before allogeneic haematopoietic stem cell transplantation in adults with acute lymphoblastic leukaemia
by Gruber et al.
www.stemcellevidence.com/alerts/artic...
Reduced-dose versus standard-dose total body irradiation before allogeneic haematopoietic stem cell transplantation in adults with acute lymphoblastic leukaemia
Comparative data on reduced-dose (8 Gy) versus standard-dose (12 Gy) total body irradiation (TBI) before allogeneic haematopoietic stem cell transplantation (allo-HSCT) for adults with acute lymphobla...
www.stemcellevidence.com
October 28, 2026 at 2:35 PM
🔗 #StemCellEvidence link to:
Reduced-dose versus standard-dose total body irradiation before allogeneic haematopoietic stem cell transplantation in adults with acute lymphoblastic leukaemia
by Gruber et al.
www.stemcellevidence.com/alerts/artic...
Reduced-dose versus standard-dose total body irradiation before allogeneic haematopoietic stem cell transplantation in adults with acute lymphoblastic leukaemia
by Gruber et al.
www.stemcellevidence.com/alerts/artic...
🔗 #StemCellEvidence link to:
Efficacy of post-transplant brentuximab vedotin maintenance by pre-transplant disease status in relapsed/refractory classic Hodgkin lymphoma
by Desai et al.
www.stemcellevidence.com/alerts/artic...
Efficacy of post-transplant brentuximab vedotin maintenance by pre-transplant disease status in relapsed/refractory classic Hodgkin lymphoma
by Desai et al.
www.stemcellevidence.com/alerts/artic...
Efficacy of post-transplant brentuximab vedotin maintenance by pre-transplant disease status in relapsed/refractory classic Hodgkin lymphoma
Patients with classic Hodgkin lymphoma (cHL) with primary refractory disease, early relapse, or extranodal disease have a higher risk of relapse after salvage therapy and autologous stem cell transpla...
www.stemcellevidence.com
October 27, 2026 at 2:26 PM
🔗 #StemCellEvidence link to:
Efficacy of post-transplant brentuximab vedotin maintenance by pre-transplant disease status in relapsed/refractory classic Hodgkin lymphoma
by Desai et al.
www.stemcellevidence.com/alerts/artic...
Efficacy of post-transplant brentuximab vedotin maintenance by pre-transplant disease status in relapsed/refractory classic Hodgkin lymphoma
by Desai et al.
www.stemcellevidence.com/alerts/artic...
➡️ New from the #StemCellEvidence alert:
📑 Induction and extended consolidation with daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone in patients with high-risk multiple myeloma (OPTIMUM/MUKnine) (...)
by Kaiser et al.
🔗Link in the comments
#MedSky
📑 Induction and extended consolidation with daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone in patients with high-risk multiple myeloma (OPTIMUM/MUKnine) (...)
by Kaiser et al.
🔗Link in the comments
#MedSky
October 26, 2026 at 8:02 AM
➡️ New from the #StemCellEvidence alert:
📑 Induction and extended consolidation with daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone in patients with high-risk multiple myeloma (OPTIMUM/MUKnine) (...)
by Kaiser et al.
🔗Link in the comments
#MedSky
📑 Induction and extended consolidation with daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone in patients with high-risk multiple myeloma (OPTIMUM/MUKnine) (...)
by Kaiser et al.
🔗Link in the comments
#MedSky
🔗 #StemCellEvidence link to:
Induction and extended consolidation with daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone in patients with high-risk multiple myeloma (OPTIMUM/MUKnine) (...)
by Kaiser et al.
www.stemcellevidence.com/alerts/artic...
Induction and extended consolidation with daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone in patients with high-risk multiple myeloma (OPTIMUM/MUKnine) (...)
by Kaiser et al.
www.stemcellevidence.com/alerts/artic...
Induction and extended consolidation with daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone in patients with high-risk multiple myeloma (OPTIMUM/MUKnine): 5-year follow-up of ...
BACKGROUND: High-risk multiple myeloma, defined by two or more high-risk cytogenetic abnormalities (HRCAs), high-risk gene expression profiling (GEP), or plasma cell leukaemia, remains associated with...
www.stemcellevidence.com
October 26, 2026 at 8:03 AM
🔗 #StemCellEvidence link to:
Induction and extended consolidation with daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone in patients with high-risk multiple myeloma (OPTIMUM/MUKnine) (...)
by Kaiser et al.
www.stemcellevidence.com/alerts/artic...
Induction and extended consolidation with daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone in patients with high-risk multiple myeloma (OPTIMUM/MUKnine) (...)
by Kaiser et al.
www.stemcellevidence.com/alerts/artic...
🟣The #StemCellEvidence alert - October 2026, is out!
🔗See the link in the comments for the top 10 articles
#MedSky
🔗See the link in the comments for the top 10 articles
#MedSky
October 22, 2026 at 12:28 PM
🟣The #StemCellEvidence alert - October 2026, is out!
🔗See the link in the comments for the top 10 articles
#MedSky
🔗See the link in the comments for the top 10 articles
#MedSky
🆕From the #StemCellEvidence alert:
📑A phase II multicenter prospective study to evaluate the safety and efficacy of myeloablative-dose treosulfan plus fludarabine (FT14) conditioning regimen in allogeneic hematopoietic stem cell transplantation (...)
by Avenoso et al
Link in the comments
#MedSky
📑A phase II multicenter prospective study to evaluate the safety and efficacy of myeloablative-dose treosulfan plus fludarabine (FT14) conditioning regimen in allogeneic hematopoietic stem cell transplantation (...)
by Avenoso et al
Link in the comments
#MedSky
October 23, 2026 at 6:35 AM
🆕From the #StemCellEvidence alert:
📑A phase II multicenter prospective study to evaluate the safety and efficacy of myeloablative-dose treosulfan plus fludarabine (FT14) conditioning regimen in allogeneic hematopoietic stem cell transplantation (...)
by Avenoso et al
Link in the comments
#MedSky
📑A phase II multicenter prospective study to evaluate the safety and efficacy of myeloablative-dose treosulfan plus fludarabine (FT14) conditioning regimen in allogeneic hematopoietic stem cell transplantation (...)
by Avenoso et al
Link in the comments
#MedSky
#StemCellEvidence link to:
A phase II multicenter prospective study to evaluate the safety and efficacy of myeloablative-dose treosulfan plus fludarabine (FT14) conditioning regimen (...)
by Avenoso et al
www.stemcellevidence.com/alerts/artic...
A phase II multicenter prospective study to evaluate the safety and efficacy of myeloablative-dose treosulfan plus fludarabine (FT14) conditioning regimen (...)
by Avenoso et al
www.stemcellevidence.com/alerts/artic...
A phase II multicenter prospective study to evaluate the safety and efficacy of myeloablative-dose treosulfan plus fludarabine (FT14) conditioning regimen in allogeneic hematopoietic stem cell transpl...
Evidences supporting the use of myeloablative-dose Treosulfan combined with Fludarabine remain largely retrospective, with outdated prospective studies available. In this phase II multicenter prospect...
www.stemcellevidence.com
October 23, 2026 at 6:36 AM
#StemCellEvidence link to:
A phase II multicenter prospective study to evaluate the safety and efficacy of myeloablative-dose treosulfan plus fludarabine (FT14) conditioning regimen (...)
by Avenoso et al
www.stemcellevidence.com/alerts/artic...
A phase II multicenter prospective study to evaluate the safety and efficacy of myeloablative-dose treosulfan plus fludarabine (FT14) conditioning regimen (...)
by Avenoso et al
www.stemcellevidence.com/alerts/artic...
🟣From the #StemCellEvidence alert:
📑Single-cell analysis of adaptive NK and CMV-specific T-cell dynamics after allogeneic HSCT
by Häkkinen et al.
🔗Link in the comments
📑Single-cell analysis of adaptive NK and CMV-specific T-cell dynamics after allogeneic HSCT
by Häkkinen et al.
🔗Link in the comments
October 13, 2026 at 6:41 AM
🟣From the #StemCellEvidence alert:
📑Single-cell analysis of adaptive NK and CMV-specific T-cell dynamics after allogeneic HSCT
by Häkkinen et al.
🔗Link in the comments
📑Single-cell analysis of adaptive NK and CMV-specific T-cell dynamics after allogeneic HSCT
by Häkkinen et al.
🔗Link in the comments
🔗 #StemCellEvidence link to:
Single-cell analysis of adaptive NK and CMV-specific T-cell dynamics after allogeneic HSCT
by Häkkinen et al.
www.stemcellevidence.com/alerts/artic...
#MedSky
Single-cell analysis of adaptive NK and CMV-specific T-cell dynamics after allogeneic HSCT
by Häkkinen et al.
www.stemcellevidence.com/alerts/artic...
#MedSky
Single-cell analysis of adaptive NK and CMV-specific T-cell dynamics after allogeneic HSCT
Cytomegalovirus (CMV) reactivation reshapes immune reconstitution and remains a significant cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (HSCT). To underst...
www.stemcellevidence.com
October 13, 2026 at 6:42 AM
🔗 #StemCellEvidence link to:
Single-cell analysis of adaptive NK and CMV-specific T-cell dynamics after allogeneic HSCT
by Häkkinen et al.
www.stemcellevidence.com/alerts/artic...
#MedSky
Single-cell analysis of adaptive NK and CMV-specific T-cell dynamics after allogeneic HSCT
by Häkkinen et al.
www.stemcellevidence.com/alerts/artic...
#MedSky
➡️ New from the #StemCellEvidence alert:
📑 Donor HLA-E*01:06 Confers Protection from Relapse and Improved Survival after T-Cell Depleted Matched Unrelated Donor Hematopoietic Cell Transplantation by Lucas et al.
🔗 Link in the comments
#MedSky
📑 Donor HLA-E*01:06 Confers Protection from Relapse and Improved Survival after T-Cell Depleted Matched Unrelated Donor Hematopoietic Cell Transplantation by Lucas et al.
🔗 Link in the comments
#MedSky
October 12, 2026 at 6:41 AM
➡️ New from the #StemCellEvidence alert:
📑 Donor HLA-E*01:06 Confers Protection from Relapse and Improved Survival after T-Cell Depleted Matched Unrelated Donor Hematopoietic Cell Transplantation by Lucas et al.
🔗 Link in the comments
#MedSky
📑 Donor HLA-E*01:06 Confers Protection from Relapse and Improved Survival after T-Cell Depleted Matched Unrelated Donor Hematopoietic Cell Transplantation by Lucas et al.
🔗 Link in the comments
#MedSky
🔗 #StemCellEvidence link to:
Donor HLA-E*01:06 Confers Protection from Relapse and Improved Survival after T-Cell Depleted Matched Unrelated Donor Hematopoietic Cell Transplantation by Lucas et al.
www.stemcellevidence.com/alerts/artic...
#MedSky
Donor HLA-E*01:06 Confers Protection from Relapse and Improved Survival after T-Cell Depleted Matched Unrelated Donor Hematopoietic Cell Transplantation by Lucas et al.
www.stemcellevidence.com/alerts/artic...
#MedSky
Donor HLA-E*01:06 Confers Protection from Relapse and Improved Survival after T-Cell Depleted Matched Unrelated Donor Hematopoietic Cell Transplantation
Hematopoietic cell transplantation (HCT) is the gold standard curative therapy for many hematological malignancies, but disease relapse is common and the primary cause of treatment failure. While the ...
www.stemcellevidence.com
October 12, 2026 at 6:42 AM
🔗 #StemCellEvidence link to:
Donor HLA-E*01:06 Confers Protection from Relapse and Improved Survival after T-Cell Depleted Matched Unrelated Donor Hematopoietic Cell Transplantation by Lucas et al.
www.stemcellevidence.com/alerts/artic...
#MedSky
Donor HLA-E*01:06 Confers Protection from Relapse and Improved Survival after T-Cell Depleted Matched Unrelated Donor Hematopoietic Cell Transplantation by Lucas et al.
www.stemcellevidence.com/alerts/artic...
#MedSky